Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

ABSTRACT:

Background

A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases. Because of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit from initial active surveillance. We aimed to characterise the time to initiation of systemic therapy in patients with metastatic renal-cell carcinoma under active surveillance.

Methods

In this prospective phase 2 trial, we enrolled patients with treatment-naive, asymptomatic, metastatic renal-cell carcinoma from five hospitals in the USA, Spain, and the UK. Patients were radiographically assessed at baseline, every 3 months for year 1, every 4 months for year 2, then every 6 months thereafter. Patients continued on observation until initiation of systemic therapy for

SUBMITTER: Rini BI 

PROVIDER: S-EPMC9199453 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature